利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

211 条记录 (耗时 0.038 秒)

    USE OF RESERVATROL FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    5.
    发明申请
    USE OF RESERVATROL FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 审中-公开

    公开(公告)号：US20190209488A1

    公开(公告)日：2019-07-11

    申请号：US16327708

    申请日：2017-08-25

    申请人： Marios Andreou Theodotou

    发明人： Marios Andreou Theodotou

    IPC分类号： A61K31/05 ,  A61K9/50 ,  A61P1/16

    CPC分类号： A61K31/05 ,  A61K9/50 ,  A61P1/16

    摘要： Micronized trans-resveratrol is provided in 50-200 mg unit dosage form for use as a single unit dose daily for administration to human patients the treatment or prevention of non-alcoholic fatty liver disease and/or for the treatment, prevention or reversal of non-alcoholic hepatic steatosis, e.g. for administration to patients exhibiting evidence of fatty liver on ultrasonography. A reported study shows the effects of resveratrol micronized formulation in reducing the liver fat, decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma-glutamyl transpeptidase (g-GT) and decreasing insulin resistance. At the end of the study, statistical analysis showed a strongly statistically significant reduction in the liver fat, which in some patients continued for an extended period after treatment was discontinued. These results demonstrate that use of resveratrol in micronized formulation improves features of NAFLD, prevents liver damage and that resveratrol micronized formulation can be an effective treatment for NAFLD.

    NOVEL TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASES
    9.
    发明申请
    NOVEL TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASES 审中-公开

    公开(公告)号：US20190054063A1

    公开(公告)日：2019-02-21

    申请号：US16166357

    申请日：2018-10-22

    申请人： DSM IP ASSETS B.V.

    发明人： Szabolcs PETER ,  Joseph SCHWAGER ,  Weerasinghe M. INDRASENA ,  Jaroslav A. KRALOVEC ,  Bernd MUSSLER

    IPC分类号： A61K31/355 ,  A61K31/22 ,  A61P1/16

    CPC分类号： A61K31/355 ,  A61K31/22 ,  A61P1/16

    摘要： The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.